Refuse-to-File Turns 25: New Guidance Changes In Style, But Not Substance
Executive Summary
US FDA’s revised draft guidance spelling out its policy on 'refuse-to-file' decisions differs little in substance compared to predecessor issued in 1993. But difference in style is telling sign of the times.
You may also be interested in...
Refusal Reversal: Alkermes Review Back On Track, But Could Still Be Bumpy
US FDA accepts Alkermes' NDA for depression drug after issuing refuse-to-file letter just two weeks ago; unusual move falls outside agency's guidance on RTFs because no changes were made to submission and it wasn't filed over protest.
Celgene Joins Troubled MS Club With Refuse To File For Ozanimod From US FDA
Other multiple sclerosis contenders – including Sanofi's Lemtrada, Acorda's Ampyra, and Merck KgAA's cladribine – have also been RTFed. Question now for Celgene is how long the delay will be.
Disease-Specific Drug Development Guidances Coming From US FDA In 2018
Alzheimer's disease, amyotrophic lateral sclerosis, migraine, and opioid dependence are among conditions that will get drug development guides from FDA; other guidances will address ANDA bioequivalence studies, shared REMS, and continuous manufacturing.